Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial
Shabir A Madhi, Eleonora Aml Mutsaerts, Alane Izu, Welekazi Boyce, Sutika Bhikha, Benit T Ikulinda, Lisa Jose, Anthonet Koen, Amit J Nana, Andrew Moultrie, Lucy Roalfe, Adam Hunt, David Goldblatt, Clare L Cutland, Jeffrey R Dorfman, Shabir A Madhi, Eleonora Aml Mutsaerts, Alane Izu, Welekazi Boyce, Sutika Bhikha, Benit T Ikulinda, Lisa Jose, Anthonet Koen, Amit J Nana, Andrew Moultrie, Lucy Roalfe, Adam Hunt, David Goldblatt, Clare L Cutland, Jeffrey R Dorfman
Abstract
Background: Routine childhood immunisation with pneumococcal conjugate vaccine (PCV) has changed the epidemiology of pneumococcal disease across age groups, providing an opportunity to reconsider PCV dosing schedules. We aimed to evaluate the post-booster dose immunogenicity of ten-valent (PCV10) and 13-valent (PCV13) PCVs between infants randomly assigned to receive a single-dose compared with a two-dose primary series.
Methods: We did an open-label, non-inferiority, randomised study in HIV-unexposed infants at a single centre in Soweto, South Africa. Infants were randomly assigned to receive one priming dose of PCV10 or PCV13 at ages 6 weeks (6w + 1 PCV10 and 6w + 1 PCV13 groups) or 14 weeks (14w + 1 PCV10 and 14w + 1 PCV13 groups) or two priming doses of PCV10 or PCV13, one each at ages 6 weeks and 14 weeks (2 + 1 PCV10 and 2 + 1 PCV13 groups); all participants then received a booster dose of PCV10 or PCV13 at 40 weeks of age. The primary endpoint was geometric mean concentrations (GMCs) of serotype-specific IgG 1 month after the booster dose, which was assessed in all participants who received PCV10 or PCV13 as per the assigned randomisation group and for whom laboratory results were available at that timepoint. The 1 + 1 vaccine schedule was considered non-inferior to the 2 + 1 vaccine schedule if the lower bound of the 96% CI for the GMC ratio was greater than 0·5 for at least ten PCV13 serotypes and eight PCV10 serotypes. Safety was a secondary endpoint. This trial is registered with ClinicalTrials.gov (NCT02943902) and is ongoing.
Findings: Of 1695 children assessed, 600 were enrolled and randomly assigned to one of the six groups between Jan 9 and Sept 20, 2017; 542 were included in the final analysis of the primary endpoint (86-93 per group). For both PCV13 and PCV10, a 1+1 dosing schedule (either beginning at 6 or 14 weeks) was non-inferior to a 2 + 1 schedule. For PCV13, the lower limit of the 96% CI for the ratio of GMCs between the 1 + 1 and 2 + 1 groups was higher than 0·5 for ten serotypes in the 6w+1 group (excluding 6B, 14, and 23F) and 11 serotypes in the 14w + 1 group (excluding 6B and 23F). For PCV10, the lower limit of the 96% CI for the ratio of GMCs was higher than 0·5 for all ten serotypes in the 6w+1 and 14w + 1 groups. 84 serious adverse events were reported in 72 (12%) of 600 participants. 15 occurred within 28 days of vaccination, but none were considered to be related to PCV injection. There were no cases of culture-confirmed invasive pneumococcal disease.
Interpretation: The non-inferiority in post-booster immune responses following a single-dose compared with a two-dose primary series of PCV13 or PCV10 indicates the potential for reducing PCV dosing schedules from a 2 + 1 to 1 + 1 series in low-income and middle-income settings with well established PCV immunisation programmes.
Funding: The Bill & Melinda Gates Foundation (OPP1 + 152352).
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Figures
References
- WHO Pneumococcal vaccines WHO position paper—2012. Wkly Epidemiol Rec. 2012;87:129–144.
- Conklin L, Loo JD, Kirk J. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33(suppl 2):S109–S118.
- Whitney CG, Pilishvili T, Farley MM. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495–1502.
- Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018;67:367–374.
- Klugman KP, Madhi SA, Adegbola RA, Cutts F, Greenwood B, Hausdorff WP. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine. 2011;29:3372–3373.
- Käyhty H, Auranen K, Nohynek H, Dagan R, Mäkelä H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines. 2006;5:651–667.
- Voysey M, Fanshawe TR, Kelly DF. Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries. Clin Infect Dis. 2018;66:913–920.
- Choi YH, Andrews N, Miller E. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2 + 1 to 1 + 1 in England and Wales: a modelling study. PLoS Med. 2019;16
- Choi YH, Melegaro, A, van Hoek AJ, Roca A, Mackenzie G, Gay N. Impact of thirteen-valent pneumococcal conjugate vaccine on pneumococcal carriage in different countries—mathematical modelling study. Poster presentation at ISPPD-9; Hyderabad, India, 2014.
- Le Polain de Waroux O, Flasche S, Prieto-Merino D, Edmunds WJ. Age-dependent prevalence of nasopharyngeal carriage of Streptococcus pneumoniae before conjugate vaccine introduction: a prediction model based on a meta-analysis. PLoS One. 2014;9
- Shiri T, Auranen K, Nunes MC. Dynamics of pneumococcal transmission in vaccine-naive children and their HIV-infected or HIV-uninfected mothers during the first 2 years of life. Am J Epidemiol. 2013;178:1629–1637.
- Shiri T, Datta S, Madan J. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e51–e59.
- von Gottberg A, de Gouveia L, Tempia S. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;371:1889–1899.
- Flasche S, Van Hoek AJ, Goldblatt D. The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries. PLoS Med. 2015;12
- Joint Committee on Vaccination and Immunisation Minutes of the Joint Committee on Vaccination and Immunisation meeting on Oct 4, 2017.
- Wernette CM, Frasch CE, Madore D. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514–519.
- Goldblatt D, Plikaytis BD, Akkoyunlu M. Establishment of a new human pneumococcal standard reference serum, 007sp. Clin Vaccine Immunol. 2011;18:1728–1736.
- Rose CE, Romero-Steiner S, Burton RL. Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol. 2011;18:135–142.
- Siber GR, Chang I, Baker S. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816–3826.
- Rüger B. Das maximale signifikanzniveau des Tests: LehneH0 ab, wenn k unter n gegebenen tests zur ablehnung führen. Metrika. 1978;25:171–178.
- Goldblatt D, Southern J, Andrews NJ. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial. Lancet Infect Dis. 2018;18:171–179.
- Scott JA, Ojal J, Ashton L, Muhoro A, Burbidge P, Goldblatt D. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis. 2011;53:663–670.
- Tashani M, Jayasinghe S, Harboe ZB, Rashid H, Booy R. Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction. World J Clin Pediatr. 2016;5:311–318.
- von Gottberg A, Cohen C, de Gouveia L. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003–2008. Vaccine. 2013;31:4200–4208.
- Gidding HF, McCallum L, Fathima P. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1·4 million children in Australia. Vaccine. 2018;36:2650–2656.
- Cohen C, von Mollendorf C, de Gouveia L. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study. Lancet Glob Health. 2017;5:e359–e369.
- Nzenze SA, Madhi SA, Shiri T. Imputing the direct and indirect effectiveness of childhood pneumococcal conjugate vaccine against invasive pneumococcal disease by surveying temporal changes in nasopharyngeal pneumococcal colonization. Am J Epidemiol. 2017;186:435–444.
- Nzenze SA, von Gottberg A, Shiri T. Temporal changes in pneumococcal colonization in HIV-infected and HIV-uninfected mother–child pairs following transitioning from 7-valent to 13-valent pneumococcal conjugate vaccine, Soweto, South Africa. J Infect Dis. 2015;212:1082–1092.
- Nzenze SA, Shiri T, Nunes MC. Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. Pediatr Infect Dis J. 2013;32:1270–1278.
- National Institute for Communicable Diseases Cumulative invasive pneumococcal disease case numbers reported by the GERMS-SA surveillance programme, 1 January 2012 to 30 April 2019.
- Tricarico S, McNeil HC, Cleary DW. Pneumococcal conjugate vaccine implementation in middle-income countries. Pneumonia (Nathan) 2017;9:6.
- Fridh Å, Bastin J, Bertot E. Gavi: 2017 progress report.
Source: PubMed